P63 expression in normal, hyperplastic and malignant breast tissues

被引：61

作者：

Wang X. ^{[1
]}

Mori I. ^{[1
]}

Tang W. ^{[1
]}

Nakamura M. ^{[1
]}

Nakamura Y. ^{[1
]}

Sato M. ^{[1
]}

Sakurai T. ^{[2
]}

Kakudo K. ^{[1
]}

机构：

[1] Department of Pathology, Wakayama Medical University, Wakayama 641-0012, 811 1 Kpmlidera, Wakayama City

[2] Department of Surgery, Kihoku Affiliated Hospital, Wakayama Medical Universlly

来源：

Breast Cancer | 2002年 / 9卷 / 3期

关键词：

Atypical ductal hyperplasia; Breast cancer; Ductal carcinoma in situ; Ductal intraepithelial neoplasia; Immunohistochemistr; Intraductal hyperplasia; p63;

D O I：

10.1007/BF02967592

中图分类号：

学科分类号：

摘要：

Background: p63 is a homologue of the p53 tumor suppressor gene and its protein is selectively expressed in the basal cells of a variety of epithelial tissues. It has recently been confirmed that p63 is expressed in the basal cells of normal prostate glands but not in prostatic carcinomas. Whether expression of p63 in breast correlates with tumor progression is the focus of this study. Methods: Forty cases, which all contained normal breast tissue, ductal hyperplasia, ductal carcinoma in situ and invasive ductal carcinoma in the same patient were included in this investigation using an indirect immunohistochemical method and double staining. Results: p63 was exclusively expressed in the myoepithelial cells of normal breast, partially expressed in ductal hyperplasia, rarely expressed in carcinoma in situ and not expressed in invasive carcinomas. Conclusions: The results suggest an association between loss of p63 expression and progression of breast ductal carcinoma, p63 immunostaining might be of assistance for distinguishing invasive ductal carcinoma from ductal carcinoma in situ or rare questionable ductal hyperplastic lesions, leading to correct therapy clinically. Breast Cancer 9:216-219, 2002.

引用

页码：216 / 219

页数：3

共 17 条

[1]

Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F., P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities, Molecular Cell, 2, 3, pp. 305-316, (1998)

[2]

Parsa R., Yang A., McKeon F., Green H., Association of p63 with proliferative potential in normal and neoplastic human keratinocytes, Journal of Investigative Dermatology, 113, 6, pp. 1099-1105, (1999)

[3]

Signoretti S., Waltregny D., Dilks J., Et al., P63 is a prostate basal cell marker and is required for prostate development, Am J Pathol, 157, pp. 1769-1775, (2000)

[4]

Tavassoli F.A., Ductal intraepithelial neoplasia (IDH, AIDH and DCIS), Breast Cancer, 7, pp. 315-320, (2000)

[5]

Trink B., Okami K., Wu L., Et al., A new human p53 homologue, Nat Med, 248, pp. 603-607, (1998)

[6]

Strano S., Rossi M., Fontemaggi G., Munarriz E., Soddu S., Sacchi A., Blandino G., From p63 to p53 across p73, FEBS Letters, 490, 3, pp. 163-170, (2001)

[7]

Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., McKeon F., P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development, Nature, 398, 6729, pp. 714-718, (1999)

[8]

Mills A.A., Zheng B., Wang X.-J., Vogel H., Roop D.R., Bradley A., P63 is a p53 homologue required for limb and epidermal morphogenesis, Nature, 398, 6729, pp. 708-713, (1999)

[9]

Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C., A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain, Molecular and Cellular Biology, 21, 5, pp. 1874-1887, (2001)

[10]

De Laurenzi V., Melino G., Evolution of functions within the p53/p63/p73 family, Annals of the New York Academy of Sciences, 926, pp. 90-100, (2000)

← 1 2 →